IMNM

Immunome, Inc. is a biopharmaceutical innovator headquartered in Exton, Pennsylvania, dedicated to the development of novel antibody therapies targeting oncology and infectious diseases. Utilizing its proprietary platform for therapeutic antibody identification, the company is advancing a robust pipeline that addresses critical unmet medical needs in various challenging disease areas. By leveraging the power of the immune system, Immunome aims to transform treatment strategies, presenting a compelling investment opportunity in the biotechnology sector for institutional investors.